The HIV-1 Envelope Glycoprotein C3/V4 Region Defines a Prevalent Neutralization Epitope following Immunization
dc.contributor.author | Lei, L. | |
dc.contributor.author | Yang, Y.R. | |
dc.contributor.author | Tran, K. | |
dc.date.accessioned | 2019-09-13T17:02:31Z | |
dc.date.available | 2019-09-13T17:02:31Z | |
dc.date.issued | 2019 | |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063733455&doi=10.1016%2fj.celrep.2019.03.039&partnerID=40&md5=0b205d6fc3e4546537fef2efb343ed5f | |
dc.identifier.uri | http://hdl.handle.net/10713/10786 | |
dc.description.abstract | Lei et al. find that monoclonal antibodies elicited by an HIV-1 Env immunogen in guinea pigs converge on the Env C3/V4 region, similar to antibody responses that occur in HIV natural infections. Molecular and computational analyses suggest that the HIV Env C3/V4 region may be exploited as a vaccine target. Copyright 2019 The Author(s)Despite recent progress in engineering native trimeric HIV-1 envelope glycoprotein (Env) mimics as vaccine candidates, Env trimers often induce vaccine-matched neutralizing antibody (NAb) responses. Understanding the specificities of autologous NAb responses and the underlying molecular mechanisms restricting the neutralization breadth is therefore informative to improve vaccine efficacy. Here, we delineate the response specificity by single B cell sorting and serum analysis of guinea pigs immunized with BG505 SOSIP.664 Env trimers. Our results reveal a prominent immune target containing both conserved and strain-specific residues in the C3/V4 region of Env in trimer-vaccinated animals. The defined NAb response shares a high degree of similarity with the early NAb response developed by a naturally infected infant from whom the HIV virus strain BG505 was isolated and later developed a broadly NAb response. Our study describes strain-specific responses and their possible evolution pathways, thereby highlighting the potential to broaden NAb responses by immunogen re-design. Copyright 2019 The Author(s) | en_US |
dc.description.sponsorship | This study was supported by NIH/National Institute of Allergy and Infectious Diseases (NIAID) grants R01AI102766, P01AI104722, UM1AI100663 and Bill and Melinda Gates Foundation grants OPP1084519 and OPP1115782. | en_US |
dc.description.uri | https://doi.org/10.1016/j.celrep.2019.03.039 | en_US |
dc.language.iso | en-US | en_US |
dc.publisher | Elsevier B.V. | en_US |
dc.relation.ispartof | Cell Reports | |
dc.subject | HIV-1 Envelope Glycoprotein | en_US |
dc.subject.mesh | Antibodies, Neutralizing | en_US |
dc.title | The HIV-1 Envelope Glycoprotein C3/V4 Region Defines a Prevalent Neutralization Epitope following Immunization | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1016/j.celrep.2019.03.039 | |
dc.identifier.pmid | 30970260 |